78 related articles for article (PubMed ID: 8873394)
21. HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping.
Hoelscher M; Hanker S; Barin F; Cheingsong-Popov R; Dietrich U; Jordan-Harder B; Olaleye D; Nägele E; Markuzzi A; Mwakagile D; Minja F; Weber J; Gürtler L; Von Sonnenburg F
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):139-49. PubMed ID: 9462924
[TBL] [Abstract][Full Text] [Related]
22. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.
Fouts TR; Tuskan RG; Chada S; Hone DM; Lewis GK
Vaccine; 1995 Dec; 13(17):1697-705. PubMed ID: 8719522
[TBL] [Abstract][Full Text] [Related]
23. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
Bckström M; Holmgren J; Schödel F; Lebens M
Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
[TBL] [Abstract][Full Text] [Related]
24. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
Zaghouani H; Anderson SA; Sperber KE; Daian C; Kennedy RC; Mayer L; Bona CA
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):631-5. PubMed ID: 7831341
[TBL] [Abstract][Full Text] [Related]
25. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
26. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
27. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
[TBL] [Abstract][Full Text] [Related]
28. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
29. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
30. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
[TBL] [Abstract][Full Text] [Related]
31. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
[TBL] [Abstract][Full Text] [Related]
32. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
[TBL] [Abstract][Full Text] [Related]
33. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
34. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
35. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
36. Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies.
Toriyoshi H; Shioda T; Sato H; Sakaguchi M; Eda Y; Tokiyoshi S; Kato K; Nohtomi K; Kusagawa S; Taniguchi K; Shiino T; Kato A; Foongladda S; Linkanonsakul S; Oka SI; Iwamoto A; Wasi C; Nagai Y; Takebe Y
AIDS Res Hum Retroviruses; 1999 Aug; 15(12):1109-20. PubMed ID: 10461831
[TBL] [Abstract][Full Text] [Related]
37. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity.
Xiao X; Phogat S; Shu Y; Phogat A; Chow YH; Wei OL; Goldstein H; Broder CC; Dimitrov DS
Vaccine; 2003 Oct; 21(27-30):4275-84. PubMed ID: 14505910
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.
Lukashov VV; Cornelissen MT; Goudsmit J; Papuashvilli MN; Rytik PG; Khaitov RM; Karamov EV; de Wolf F
AIDS; 1995 May; 9(5):435-9. PubMed ID: 7639968
[TBL] [Abstract][Full Text] [Related]
39. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
40. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L
J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
